Antibody–drug conjugates improve outcomes for patients with inoperable or metastatic Breast Cancer – European Society for Medical Oncology

ESMO – European Society for Medical Oncology shared a post on LinkedIn:

“Antibody–drug conjugates improve outcomes for patients with inoperable or metastatic Breast Cancer.
At ESMO23, a Presidential Symposium presentation of TROPION-Breast01 trial showed that datopotamab deruxtecan significantly improved PFS compared to chemotherapy in previously treated patients with HR+/HER2- disease.
Also, updated survival data from the DESTINY-Breast04 trial indicate a sustained OS benefit in patients with HER2-low disease treated with trastuzumab deruxtecan.

On the ESMO Daily Reporter, check out the full data from the two studies commented by Sarat Chandarlapaty, New York, USA.”

For details click here.
Source: ESMO – European Society for Medical Oncology/LinkedIn